Related Experiment Videos

Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term

Clinical Cardiology
|February 1, 1987
PubMed

Insights

Atenolol and hydrochlorothiazide, used for hypertension, differently impact serum lipoproteins. Atenolol lowers HDL cholesterol, while hydrochlorothiazide raises triglycerides and LDL cholesterol over time.

Area of Science:

  • Cardiovascular Pharmacology
  • Clinical Lipidology
  • Hypertension Management

Background:

  • Essential hypertension is a common cardiovascular risk factor.
  • Lipoprotein profiles are critical indicators of cardiovascular health.
  • Understanding medication effects on lipids is vital for patient management.

Purpose of the Study:

  • To investigate the long-term influence of atenolol and hydrochlorothiazide on serum lipoproteins in hypertensive men.
  • To compare the differential effects of these two common antihypertensive agents on lipid profiles.

Main Methods:

  • A randomized, prospective study involving 68 men with essential hypertension.
  • Monitoring of cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoproteins AI, and B up to 42 months.
  • Analysis of changes in lipoprotein parameters following treatment with atenolol and hydrochlorothiazide.

Main Results:

  • Atenolol significantly decreased HDL cholesterol and increased triglycerides from 6 to 42 months.
  • Hydrochlorothiazide significantly increased triglycerides, LDL cholesterol, and total cholesterol from 12 to 42 months.
  • Adverse lipoprotein changes were dose-dependent with atenolol but not hydrochlorothiazide.

Conclusions:

  • Both atenolol and hydrochlorothiazide exert distinct adverse effects on serum lipoproteins during long-term administration.
  • Further research is needed to ascertain if these lipid alterations mitigate the cardiovascular benefits of blood pressure control in hypertensive patients.

Related Concept Videos